Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Subscribe To Our Newsletter & Stay Updated
